Abstract
Haemophilia is the most common congenital disorder of coagulation and affects approximately 1 in 10,000 males around the world. Haemophilia A is due to a deficiency of factor VIII in the circulating blood whilst haemophilia B (also known as Christmas disease) is a clinically identical disorder caused by factor IX deficiency. It is less common than haemophilia A and affects 1 in about 30,000 males. Both factors VIII and IX are essential glycoproteins in the clotting cascade [1] (Fig. 1). The hallmark of severe haemophilia is recurrent and spontaneous haemarthrosis, typically affecting the hinge joints such as the ankle, knee and elbow. The severity of bleeding depends upon the level of factor in the blood.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Gailani D, Broze GJ (1991) Factor IX activation in a revised model of blood coagulation.Science253: 909–912
Larsson SA (1985) Life expectancy of Swedish haemophiliacs 1831–1980.Brit J Haematol59: 593–602
Giannelli F, Choo KH, Rees DJG, Boyd Y, Rizza CR, Brownlee GG (1983) Gene deletions in patients with haemophilia B and anti-factor IX antibodies.Nature303: 181–182
Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J (1995) Haemophilia A: mutation type determines risk of inhibitor formation.Thromb Haemost74: 1402–1406
Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian HH, Negrier C, Vinciguerra C et al (1995) Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.Blood86: 2206–2212
Green PM, Giannelli F, Sommer SS, Poon M-C, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS et al (2000) Haemophilia B: database of point mutations and short additions and deletions-v9.0http://www.umds.ac.uk/molgen/haemBdatabase.html
Naylor JA, Green PM, Rizza CR, Giannelli F (1993) Analysis of factor VIII messenger RNA reveals defects in every one of 28 haemophilia A patients.Hum Mol Genet2: 11–17
Rowley G, Saad S, Giannelli F, Green PM (1995) Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage.Genomics30: 574–582
Tuddenham EGD (1994) Flip tip inversion and haemophilia A.Lancet342: 307–308
Kemball-Cook G, Tuddenham EGD, Wacey AI (1999) Haemophilia A mutation databasehttp://europium.mrc.rpms.ac.uk
Giannelli F, Green PM, Sommer SS, Poon M-C, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS et al (1998) Haemophilia B: database of point mutations and short additions and deletions: eighth edition.Nucl Acid Res26: 265–268
Taylor SAM, Dutfin J, Cameron C, Teitel J, Garvey B, Lillicrap DP (1992) Characterization of the original Christmas disease mutation (cysteine 206 ¡ªf serine): from clinical recognition to molecular pathogenesis.Thromb Haemost67: 63–65
Morgan GE, Rowley G, Green PM, Chisholm M, Giannelli F, Brownlee GG (1997) Further evidence for the importance of an androgen response element in the factor IX promoter.Brit J Haematol98: 79–85
Biggs R (1967) Thirty years of haemophilia treatment in Oxford.Brit J Haematol13: 452–463
Rosendaal FR, Varekamp I, Smit C, Brocker-Vriends AHJT, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TPBM, Briet E (1989) Mortality and causes of death in Dutch haemophiliacs 1972–86.Brit J Haematol71: 71–76
Darby SC, Ewart DW, Giangrande PLF, Dolin PJ, Spooner RJD, Rizza CR on behalf of the UKHaemophilia Centre Directors’ Organization (1995) Mortality before and after HIV infection in the complete UK population of haemophiliacs.Nature377: 79–82
Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE, for the UK Haemophilia Centre Directors’ Organization (1997) Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C.Lancet350: 1425–1431
Lee CA, Ironside JW, Bell JE, Giangrande PLF, Ludlam CA, Esiri MM, McLaughlin JE (1998) Retrospective neuropathological review of prion disease in UK haemophilic patients.Thromb Haemost80: 909–911
Katayama K, Ericsson LH, Enfield DL, Walsh KA, Neurath H, Davie EW, Titani K (1979) Comparison of amino acid sequence of bovine coagulation factor IX (Christmas factor) with that of other vitamin K-dependent plasma proteins.Proc Natl Acad Sci USA76: 4990–4994
Proudfoot NJ, Brownlee GG (1974) Sequence at the 3’ end of globin mRNA shows homology with immunoglobulin light chain mRNA.Nature252: 359–362
Winter G, Fields S, Gait MJ, Brownlee GG (1981) The use of synthetic oligodeoxynucleotide primers in cloning and sequencing segment 8 of influenza virus A/PR/8/34.Nucl Acid Res9: 237–245
Fields S, Winter G, Brownlee GG (1981) Structure of the neuraminidase gene in human influenza virus A/PR/8/34.Nature290: 213–217
Choo KH, Gould KG, Rees DJG, Brownlee GG (1982) Molecular cloning of the gene for human antihaemophilic factor IX.Nature299: 178–180
Wallace RB, Johnson MJ, Hirose T, Miyake T, Kawashima EH, Itakura K (1981) The use of synthetic oligonucleotides as hybridization probes: II. Hybridization of oligonucleotides of mixed sequence to rabbit (l-globin DNA.Nucl Acid Res9: 879–898
Kurachi K, Davie EW (1982) Isolation and characterization of a cDNA coding for human factor IX.Proc Natl Acad Sci USA79: 6461–6464
Jaye M, de la Salle H, Schamber F, Balland A, Kohli V, Findeli A, Tolstoshev P, Lecocq J-P (1983) Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe derived from the amino acid sequence of bovine factor IX.Nucl Acid Res11: 2325–2335
Anson DS, Choo KH, Rees DJG, Giannelli F, Gould K, Huddleston JA, Brownlee GG (1984) Gene structure of human anti-haemophilic factor IX.EMBO J3: 1053–1064
Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K (1985) Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).Biochemistry24: 3736–3750
Bentley AK, Rees DJG, Rizza C, Brownlee GG (1986) Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position-4.Cell45: 343–348
Anson DS, Austen DEG, Brownlee GG (1985) Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells.Nature315: 683–685
Anson DS, Brownlee GG, Jones IM (1992) Factor IX preparations uncontaminated by plasma components or poxvirus.US patent no.5,171,569
Busby S, Kumar A, Joseph M, Halfpap L, Insley M, Berkner K, Kurachi K, Woodbury R (1985) Expression of active human factor IX in transfected cells.Nature316: 271–273
de la Salle H, Altenburger W, Elkaim R, Dott K, Dieterle A, Drillien R, Cazenave J-P, Tolstoshev P, Lecocq J-P (1985) Active y-carboxylated human factor IX expressed using recombinant DNA techniques.Nature316: 268–270
Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB (1986) Expression, purification and characterization of recombinant y-carboxylated factor IX synthesized in chinese hamster ovary cells.J Biol Chem261: 9622–9628
Rehemtulla A, Roth DA, Wasley LC, Kuliopulos A, Walsh CT, Furie B, Furie BC, Kaufman RJ (1993) In vitro and in vivo functional characterization of bovine vitamin K-dependent ‘y-carboxylase expressed in chinese hamster ovary cells.Proc Natl Acad Sci USA90: 4611–4615
Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ (1993) PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.J Biol Chem268: 8458–8465
White GC, Beebe A, Nielsen B (1997) Recombinant factor IX.Thromb Haemost78: 261–265
Gillis S, Furie BC, Furie B, Patel H, Huberty MC, Switzer M, Foster WB, Scoble HA, Bond MD (1997) y-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.Protein Sci6: 185–196
Brownlee GG, Rizza C (1984) Clotting factor VIII cloned.Nature312: 307
Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL et al (1984) Expression of active human factor VIII from recombinant DNA clones.Nature312: 330–337
Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC et al (1984) Molecular cloning of a eDNA encoding human antihaemophilic factor.Nature312: 342–347
Pipe SW, Morris JA, Shah J, Kaufman R (1998) Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin.Proc Nall Acad Sci USA273: 8537–8544
Kaufman RJ, Wasley LC, Darner AJ (1988) Synthesis, processing and secretion of recombinant factor VIII expressed in mammalian cells.J Biol Chem263: 6352–6362
Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ (1989) Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in chinese hamster ovary cells.Mol Cell Biol9: 1233–1242
Kaufman RJ (1992) Expression and structure-function properties of recombinant factor VIII.Transfos Med Rev6: 235–246
Gomperts E, Lundblad R, Adamson R (1992) The manufacturing process of recombinant factor VIII, Recombinate.Transfos Med Rev6: 247–251
Chan SY, Lembach KJ (1991) Genetic characterization of recombinbant BHK-21 cells expressing factor VIII.Semin Hematol28: 10–16
Klein U (1991) Production and characterization of recombinant factor VIII.Semin Hematol28: 17–21
Berntop E (1997) Second generation, B-domain deleted recombinant factor VIII.Thromb Haemost78: 256–265
Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman R (1986) A large region (c 95 kDa) of human factor VIII is dispensable forin vitroprocoagulant activity.Proc Nad Acad Sci USA83: 5939–5942
Andersson L-O, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J (1986) Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.Proc Nail Acad Sci USA83: 2979–2983
Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Wehar GA, Gorman C (1986) Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.Biochemistry25: 8343–8347
Lind P, Larsson K, Spira J, Sydow-Backman M, Almstedt A, Gray E, Sandberg H (1995) Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.Eur J Biochem232: 19–27
Lusher J, Ingerslev J, Roberts H, Hedner U (1998) Clinical experience with recombinant factor Vila.Blood Coagulai Fibrinolys9: 119–128
Warder I, Ewenstein BM, Koerper MA, Shapiro A, Key N, Dimichele D, Miller RT, Pasi J, Rivard GE, Sommer SS et al (1996) Factor IX inhibitors and anaphylaxis in haemophilia B.Haemophilia2: 239–260
Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK et al (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.Thromb Haemost80: 912–918
Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA (1998) Prospective, randomised trial of two doses of rVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.Thromb Haemost80: 773–778
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with haemophilia.N Engl J Med328: 453–459
Bray GL, Gomperts ED, Courter S, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M (1994) A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with haemophilia.Blood83: 2428–2435
Rothschild C, Laudan Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, Goudemand J (1998) French previously untreated patients with severe haemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance.Thromb Haemost80: 779–783
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Basel AG
About this chapter
Cite this chapter
Brownlee, G.G., Giangrande, P.L.F. (2001). Clotting factors VIII and IX. In: Buckel, P. (eds) Recombinant Protein Drugs. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8346-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8346-7_3
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9527-9
Online ISBN: 978-3-0348-8346-7
eBook Packages: Springer Book Archive